The Medical Letter on Drugs and Therapeutics
Advice for Travelers
October 7, 2019 (Issue: 1582)Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
- Vaccines for travelers. Med Lett Drugs Ther 2018; 60:185.
- NJ Ajami et al. Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med 2014; 21:6.
- FDA In Brief: FDA approves new packaging for brand-name over-the-counter loperamide to help curb abuse and misuse. September 20, 2019. Accessed September 26, 2019.
- MS Riddle et al. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. Clin Infect Dis 2008; 47:1007.
- MS Riddle et al. Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report. J Travel Med 2017; 24(suppl 1):S63.
- R Steffen et al. Traveler's diarrhea: a clinical review. JAMA 2015; 313:71.
- D Jain et al. Campylobacter species and drug resistance in a north Indian rural community. Trans R Soc Trop Med Hyg 2005; 99:207.
- DR Tribble et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.
- In brief: More fluoroquinolone warnings. Med Lett Drugs Ther 2018; 60:136.
- MS Riddle et al. Trial evaluating ambulatory therapy of travelers' diarrhea (TrEAT TD) study: a randomized controlled trial comparing 3 single-dose antibiotic regimens with loperamide. Clin Infect Dis 2017; 65:2008.
- Rifamycin (Aemcolo) for treatment of travelers' diarrhea. Med Lett Drugs Ther 2019; 61:39.
- HL DuPont et al. Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study. J Travel Med 2014; 21:369.
- KS Hong and JS Kim. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol 2011; 4:227.
- R Steffen et al. Rifamycin SV-MMX for treatment of travellers' diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria. J Travel Med 2018; 25(1).
- P Zanger et al. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis 2013; 13:946.
- Insect repellents. Med Lett Drugs Ther 2019; 61:129.
- E Mirzaian et al. Mosquito-borne illnesses in travelers: a review of risk and prevention. Pharmacotherapy 2010; 30:1031.
- DO Freedman et al. Medical considerations before international travel. N Engl J Med 2016; 375:247.
- HM Staines et al. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. J Antimicrob Chemother 2018; 73:581.
- PJ van Genderen et al. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected]. J Travel Med 2007; 14:92.
- LC Steinhardt et al. Review: malaria chemoprophylaxis for travelers to Latin America. Am J Trop Med Hyg 2011; 85:1015.
- M Tickell-Painter et al. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev 2017; 10:CD006491.
- P Schlagenhauf et al. Use of mefloquine in children – a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10:292.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 September 20 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RL Woosley et al. QT drugs list, AZCERT, Inc. Available at www.credibleMeds.org. Accessed September 26, 2019.
- CS Chu and DO Freedman. Tafenoquine and G6Pd: a primer for clinicians. J Travel Med 2019; 26(4).
- Tafenoquine (Arakoda; Krintafel) for malaria. Med Lett Drugs Ther 2019; 61:101.
- E Meltzer et al. Vivax malaria chemoprophylaxis: the role of atovaquone-proguanil compared to other options. Clin Infect Dis 2018; 66:1751.
- P Schlagenhauf et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54:e124.
- RC Mayer et al. Safety of atovaquone-proguanil during pregnancy. J Travel Med 2019; 26(4).
- MG Guzman and E Harris. Dengue. Lancet 2015; 385:453.
- MK Kindhauser et al. Zika: the origin and spread of a mosquito-borne virus. Bull World Health Organ 2016; 94:675.
- SC Weaver and M Lecuit. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231.
- F Krauer et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review. PLoS Med 2017; 14(1):e1002203.
- MA Mwachui et al. Environmental and behavioural determinants of leptospirosis transmission: a systematic review. PLoS Negl Trop Dis 2015; 9(9):e0003843.
- ND Gundacker et al. Infections associated with adventure travel: a systematic review. Travel Med Infect Dis 2017; 16:3.
- AM Luks et al. Wilderness Medical Society Practice Guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med 2019 Jun 24 (epub).
- EV Low et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ 2012; 345:e6779.
- TE Kelly and PH Hackett. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol 2010: 11:319.
- Sulfonamide cross-reactivity. Med Lett Drugs Ther 2019; 61:44.
- J Xiong et al. Efficacy of ibuprofen on prevention of high altitude headache: a systematic review and meta-analysis. PLoS One 2017; 12:e0179788.
- P Burns et al. Altitude sickness prevention with ibuprofen relative to acetazolamide. Am J Med 2019; 132:247.
- M Maggiorini et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145:497.
- E Leshem et al. Tadalafil and acetazolamide versus acetazolamide for the prevention of severe high-altitude illness. J Travel Med 2012; 19:308.
- M Izadi et al. Do pregnant women have a higher risk for venous thromboembolism following air travel? Adv Biomed Res 2015; 4:60.
- D Chandra et al. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med 2009; 151:180.
- JR Bartholomew and NS Evans. Travel-related venous thromboembolism. Vasc Med 2019; 24:93.
- MJ Clarke et al. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database Syst Rev 2016; 9:CD004002.
- MR Cesarone et al. Venous thrombosis from air travel: the LON- FLIT3 study–prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 2002; 53:1.
- C Cingi et al. Jetlag related sleep problems and their management: a review. Travel Med Infect Dis 2018; 24:59.
- J Arendt. Approaches to the pharmacological management of jet lag. Drugs 2018; 78:1419.
- V Srinivasan et al. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther 2010; 27:796.
- AO Jamieson et al. Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2001; 2:423.
- PC Zee et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med 2010; 11:525.
- WP Williams 3rd et al. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy 2016; 36:1028.
- RP Rosenberg et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc 2010; 85:630.
- A Spinks and J Wasiak. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011; (6):CD002851.
- A Koch et al. The neurophysiology and treatment of motion sickness. Dtsch Arztebl Int 2018; 115:687.
- Sunscreens. Med Lett Drugs Ther 2018; 60:129.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.